生物谷報道：最近,，科學(xué)家們發(fā)現(xiàn)30%-40%乳腺癌存活者表達乳腺癌相關(guān)基因,，這些基因未來可能是這些患者基因靶向治療最大的靶標(biāo)。這種乳腺癌原癌基因在腫瘤組織中有非常高的檢出率。這對治療許多乳腺癌患者有著非常重要的意義,。這項研究結(jié)果發(fā)表在最新一期的《Cell》雜志上。
舊的基因分類技術(shù)方法學(xué)使研究者區(qū)分兩基因困難,。,。以前科學(xué)家們每次只能評估一種基因。但是新的實驗技術(shù)每次可以評估上百種基因,。研究人員通過對1,，200的基因的篩選，發(fā)現(xiàn)5個符合要求的基因,。與此同時,，他們從患者腫瘤取出癌細胞，利用特殊方法分別關(guān)閉與已鑒別出的基因相同的基因,，尋找那些對腫瘤細胞存活發(fā)揮關(guān)鍵作用基因,。。他們發(fā)現(xiàn)這些基因不僅維持腫瘤細胞存活,，而且在其過表達時還促進腫瘤的形成,。其中與其他基因不同的是IKBKE在人類乳腺癌中明顯高表達。這種新的乳腺癌易感基因在腫瘤的形成和發(fā)展中起著及其關(guān)鍵的作用,。此基因不同于以往的乳腺癌易感基因BRCA1和BRCA2,，是先天具有的。帶有這些遺傳變異的這些基因的女性會增加早發(fā)乳腺癌的風(fēng)險,。研究者僅在乳腺癌組織中發(fā)現(xiàn)這種正常的新基因IKBKE突變而在機體其他器官并未檢測出來,。一個國際公認的加拿大乳腺癌專家認為IKBKE對了解乳腺癌的形成和發(fā)展具有標(biāo)志性的作用。
Figure 1. Activated MEK1 and AKT1 Cooperate to replace H-RASV12
AI microscopic (100–200 μm, gray), macroscopic (>200 μm, black) colonies, and tumor formation (number of tumors formed/tumor sites injected) are shown for HEK cells expressing hTERT, LT, ST, and the indicated genes. Error bars represent mean ±SD for three independent experiments.
原文出處：
Cell June 15, 2007: 129 (6)
Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogenep1065
Jesse S. Boehm, Jean J. Zhao, Jun Yao, So Young Kim, Ron Firestein, Ian F. Dunn, Sarah K. Sjostrom, Levi A. Garraway, Stanislawa Weremowicz, Andrea L. Richardson, Heidi Greulich, Carly J. Stewart, Laura A. Mulvey, Rhine R. Shen, Lauren Ambrogio, Tomoko Hirozane-Kishikawa, David E. Hill, Marc Vidal, Matthew Meyerson, Jennifer K. Grenier, Greg Hinkle, David E. Root, Thomas M. Roberts, Eric S. Lander, Kornelia Polyak, and William C. Hahn
[Summary] [Full Text] [PDF] [Supplemental Data][Comments]
相關(guān)基因：
IKBKE
Official Symbol IKBKE and Name: inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase epsilon [Homo sapiens]
Other Aliases: RP11-534L20.1, IKK-i, IKKE, IKKI, KIAA0151, MGC125294, MGC125295, MGC125297
Other Designations: IKK-related kinase epsilon; inducible IkappaB kinase
Chromosome: 1; Location: 1q32.1
Annotation: Chromosome 1, NC_000001.9 (204710418..204736844)
MIM: 605048
GeneID: 9641
作者簡介：
William C. Hahn, MD, PhD
Associate Professor of Medicine, Harvard Medical School
Department
Medical Oncology/Molecular and Cellular
Center/Program
Genitourinary Cancer
Contact Information
William C. Hahn, MD, PhD
Biography
Dr. Hahn received his MD and PhD from Harvard Medical School in 1994. He then completed clinical training in internal medicine at Massachusetts General Hospital and medical oncology at DFCI. He conducted his postdoctoral studies with Dr. Robert Weinberg at the Whitehead Institute and joined the faculty of DFCI and Harvard Medical School in 2001.
